grant

COVID Supplement - NIH Tetramer Core Facility

Organization EMORY UNIVERSITYLocation ATLANTA, UNITED STATESPosted 21 Mar 2020Deadline 20 Mar 2027
NIHUS FederalResearch GrantFY20212019 novel corona virus2019 novel coronavirus2019-nCoV2019-nCoV S protein2019-nCoV spike glycoprotein2019-nCoV spike proteinAntigen TargetingB blood cellsB cellB cellsB-CellsB-LymphocytesB-cellCD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCOVIDCOVID infected patientCOVID patientCOVID positive patientCOVID-19 S proteinCOVID-19 detectionCOVID-19 infected patientCOVID-19 patientCOVID-19 positive patientCOVID-19 spike glycoproteinCOVID-19 spike proteinCOVID-19 virusCOVID19 detectionCOVID19 S proteinCOVID19 patientCOVID19 positive patientCOVID19 spike glycoproteinCOVID19 spike proteinCOVID19 virusClass I GenesCoV diseaseCoV-2CoV2CommunitiesCore FacilityDetectionDevelopmentDevelopment and ResearchEvaluationMHC Class IMHC Class I GenesNational Institutes of HealthPopulationProcessProductionR & DR&DReagentResearchSARS corona virus 2SARS-CoV-2SARS-CoV-2 S proteinSARS-CoV-2 detectionSARS-CoV-2 infected patientSARS-CoV-2 patientSARS-CoV-2 positive patientSARS-CoV-2 spike glycoproteinSARS-CoV-2 spike proteinSARS-CoV2SARS-CoV2 S proteinSARS-CoV2 spike glycoproteinSARS-CoV2 spike proteinSARS-associated corona virus 2SARS-associated coronavirus 2SARS-coronavirus-2SARS-related corona virus 2SARS-related coronavirus 2SARSCoV2Severe Acute Respiratory Distress Syndrome CoV 2Severe Acute Respiratory Distress Syndrome Corona Virus 2Severe Acute Respiratory Distress Syndrome Coronavirus 2Severe Acute Respiratory Syndrome CoV 2Severe Acute Respiratory Syndrome-associated coronavirus 2Severe Acute Respiratory Syndrome-related coronavirus 2Severe acute respiratory syndrome associated corona virus 2Severe acute respiratory syndrome corona virus 2Severe acute respiratory syndrome coronavirus 2Severe acute respiratory syndrome coronavirus 2 S proteinSevere acute respiratory syndrome coronavirus 2 spike glycoproteinSevere acute respiratory syndrome coronavirus 2 spike proteinSevere acute respiratory syndrome related corona virus 2T-Cell EpitopesT-CellsT-LymphocyteT-Lymphocyte EpitopesT8 CellsT8 LymphocytesTechnologyUnited States National Institutes of HealthWuhan coronavirusadaptive immune responsecorona virus diseasecoronavirus diseasecoronavirus disease 2019 S proteincoronavirus disease 2019 detectioncoronavirus disease 2019 infected patientcoronavirus disease 2019 patientcoronavirus disease 2019 positive patientcoronavirus disease 2019 spike glycoproteincoronavirus disease 2019 spike proteincoronavirus disease 2019 viruscoronavirus disease infected patientcoronavirus disease patientcoronavirus disease positive patientcoronavirus patientdetect COVID-19detect COVID19detect SARS-CoV-2detect severe acute respiratory syndrome coronavirus 2developmentalhCoV19improvednCoV2patient infected with COVIDpatient infected with COVID-19patient infected with SARS-CoV-2patient infected with coronavirus diseasepatient infected with coronavirus disease 2019patient infected with severe acute respiratory syndrome coronavirus 2patient with COVIDpatient with COVID-19patient with COVID19patient with SARS-CoV-2patient with coronavirus diseasepatient with coronavirus disease 2019patient with severe acute respiratory distress syndrome coronavirus 2research and developmentresponsesevere acute respiratory syndrome coronavirus 2 detectionsevere acute respiratory syndrome coronavirus 2 infected patientsevere acute respiratory syndrome coronavirus 2 patientsevere acute respiratory syndrome coronavirus 2 positive patientthymus derived lymphocytetoolvaccine candidate
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

The NIH Tetramer Core Facility (TCF) distributes high quality reagents for detection of innate T cell and classical CD4 and CD8 T cell populations. This Facility also conducts R&D to produce new reagents and improve existing tetramer technologies. The TCF is producing MHC class I and class II tetramers for isolation and characterization of SARS-CoV2-specific CD4 and CD8 T cells, and is also developing SARS-CoV-2 Spike protein tetramers for detection and characterization of SARS-CoV2 specific B cells. Thus far, 56 MHC tetramers have been distributed to the community, an additional 35 are in-process.

Orders are expected to increase as COVID-related research increases. Additional reagents will be produced and distributed as new T cell epitopes and B cell antigen targets are identified. These tetramer reagents will be invaluable tools for evaluation of adaptive immune responses in COVID-19 patients or in response to candidate vaccines.

Grant Number: 75N93020D00005-0-759302100001-2
NIH Institute/Center: NIH
Principal Investigator: JOHN ALTMAN

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →

Explore more

📍 More grants in UNITED STATES🏷 More NIH opportunities🏷 More US Federal opportunities🏷 More Research Grant opportunities🏢 All nih_reporter opportunities